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found a weak linear association between plasma and DBS measurements of transferrin concentrations,
but a strong linear association and high level of agreement between plasma and DBS measurements of IFABP concentrations. These findings demonstrate the validity and feasibility of measuring I-FABP, but not
transferrin, using DBS sampling.
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ABSTRACT
Environmental Enteric Dysfunction (EED) is a subclinical condition characterized by
increased intestinal permeability and impaired nutrient absorption, but current methods for
assessing EED are invasive and resource intensive. Dried blood spot (DBS) biomarker sampling
offers a minimally invasive method of detecting EED. We present a validation study of two DBS
protocols for the measurement of transferrin, a biomarker of iron status, and I-FABP, a
biomarker of intestinal permeability. Matched DBS from a fingerstick and venous whole blood
samples from n=74 individuals were collected over a 3-week period. Whole blood was used to
create additional DBS samples and then spun down to plasma for analysis. We found a weak
linear association between plasma and DBS measurements of transferrin concentrations, but a
strong linear association and high level of agreement between plasma and DBS measurements of
I-FABP concentrations. These findings demonstrate the validity and feasibility of measuring IFABP, but not transferrin, using DBS sampling.
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INTRODUCTION
Chronic malnutrition is a serious global health burden which increases young children’s
risk of poor cognitive development, lost adult productivity, chronic disease infection, and
mortality. Environmental Enteric Dysfunction (EED), a subclinical gastrointestinal condition
characterized by increased intestinal permeability and reduced nutrient absorption, plays a major
role in the etiology of malnutrition. However, EED is a poorly understood disorder, in part due to
various methodological constraints for diagnosing the disease in the low-resource and/or nonclinical settings in which it is most prevalent. Thus, there exists a need for validated, fieldfriendly techniques for detecting and studying EED.
Several blood-based biomarkers of EED hold the potential to be used with a minimally
invasive, highly portable sampling technique known as dried blood spot (DBS) collection. In this
procedure, five drops of blood are collected from a simple finger stick onto a standardized filter
paper card and then dried. The present study contributes to ongoing efforts to identify and
validate DBS-based biomarkers by investigating transferrin, a biomarker of blood iron levels,
and the small intestinal fatty-acid binding protein (I-FABP), a biomarker of intestinal
permeability. The validation of additional DBS-based biomarkers of EED will strengthen our
ability to holistically evaluate this complex disorder.
BACKGROUND
Environmental Enteric Dysfunction (EED) is a subclinical gastrointestinal disorder
caused by regular oral-fecal contamination that blunts the chorionic villi, weakening the
intestinal mucosal barrier and leading to increased intestinal permeability (i.e., “leaky” gut
membrane) (Korpe and Petri, 2012; Marie et al., 2018). This permeability facilitates
translocation of bacteria and toxins into systemic circulation, and resultant systemic and
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intestinal inflammation further increase an individual’s susceptibility to other infections; in
addition, the reduced surface area of the blunted villi limits nutrient absorption and perpetuates
malnutrition (Kosek et al., 2014; Kosek et al., 2017; Tickell et al., 2019). These interdependent,
synergistic effects of EED play a major role in the etiology of malnutrition, undermining
supplementation-based interventions for malnutrition (Harper et al., 2018). Importantly, EED has
been linked to linear growth stunting, oral vaccine failure, and diarrheal diseases, the last of
which is estimated to affect 150 million children worldwide (Kosek et al., 2017; Owino et al.,
2016; Naylor et al., 2015; Sullivan, 2021).
At present, primary methods for assessing EED are invasive, resource-intensive, timeconsuming, and require significant laboratory infrastructure (Hoke et al., 2018). Using minimally
invasive biomarkers to identify children at greatest risk for EED has been recognized as a
powerful tool for clinical and research efforts (Kosek et al., 2013; Hoke et al., 2018; Harper et al.,
2018; Tickell et al., 2019; Denson, 2021). However, detecting biomarkers through the collection
of conventional biological samples (i.e. feces, urine, or whole blood) often pose several logistical
constraints in the low-resource settings in which EED is most prevalent, such as limited
laboratory access and discontinuous cold chains (Lim 2018; Hoke et al., 2018).
Dried blood spot (DBS) technology offers a minimally invasive and field-friendly
alternative for studying EED (McDade et al., 2002; McDade et al., 2007). In this method, five
drops of whole blood are collected onto standardized filter paper cards following a simple finger
stick, and then left out to dry. The standard Whatman 903 Proteinsaver Card used in DBS
collection is made up of nitrocellulose polymer networks with gap sizes specifically designed to
capture and sequester proteins. Thus, these DBS samples are stable and highly portable, and can
be transported over significant geographic distances. In the laboratory, the dried blood spots are
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later extracted as sample discs via hole punch and reconstituted in solution using reagents
specific to different enzyme-linked immunosorbent assay (ELISA) kits (McDade et al., 2002;
McDade et al., 2007).
DBS sampling reduces the logistical burdens and costs of assessing this condition for
researchers, especially in non-clinical settings (McDade et al., 2002; McDade et al., 2007).
Additionally, this sampling method reduces the physiological burden on participants, particularly
among infants, elderly individuals, or individuals with blood clotting disorders (Freeman et al.
2018). However, DBS may produce more imprecise measurements than its plasma or serum
counterparts due to the hematocrit effect, which involves the variable interference of red blood
cells in analyte extraction and measurement (Freeman et al., 2018). Because the volumetric
percentage of red blood cells influences the viscosity of whole blood, too high or low hematocrit
will result in a heterogeneous distribution of the sample and analyte on the filter paper card
(Freeman et al., 2018). In addition, variability in blood drop volume, storage conditions, and
sample reconstitution efficiency can also impede accurate detection of biomarker levels
(McDade et al., 2002; McDade et al., 2007). Therefore, any candidate blood-based biomarkers of
EED must first be validated for use with DBS sampling before field use.
To date, the only EED biomarker which has undergone rigorous assessment and
validation for measurement from DBS is endotoxin-core antibodies (EndoCAb), a measure of
microbial translocation which only captures one facet of EED (Hoke et al., 2018). However,
EED is a highly complex disorder with several, interdependent mechanisms through which it
impacts human health outcomes, and cannot be accurately diagnosed through one biomarker. In
addition, though DBS offers significant advantages for researchers and participants, the greater
variability of DBS sampling compared to venipuncture typically makes it more appropriate for
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population-level research, rather than individual, absolute clinical assessments (Samuelsson et al.,
2015). However, a combined evaluation of multiple EED biomarkers may increase the
specificity and sensitivity of this method to more precisely determine an individual’s EED status.
Transferrin, a family of glycoproteins that regulate iron transport throughout the blood
plasma, is one potential biomarker of EED-related micronutrient deficiency (Ogun and Adebayo,
2020). As a key component of various metabolic processes, iron-deficiency anemia has been
consistently linked to stunted growth among young children (Colston et al., 2019; McCormick et
al. 2019). More recently, a mouse study by Mohan Kumar and colleagues (2020) indicated that
severe anemia contributes to the destabilization of intercellular epithelial junctions, increasing
intestinal permeability and further undermining nutrient absorption in individuals with EED.
Validated DBS measures have been developed for transferrin receptors, but no such assessment
of transferrin has been completed yet (Cook et al., 1998; McDade and Shell-Duncan, 2002).
However, transferrin has been previously found to have a significant effect on short-term linear
growth, warranting investigation of its measurement with DBS sampling and as a biomarker of
EED (Colston et al., 2019).
Another potential EED biomarker is the small cytoplasmic intestinal fatty-acid binding
protein (I-FABP), which is released into circulation following damage to the epithelial cells of
the small intestinal mucosal barrier (Kanda et al., 1996; Uzun et al., 2014). Enterocyte damage is
a direct precursor to increased intestinal permeability, one of EED’s primary characteristics.
Prendergast and colleagues (2014) previously found a significant relationship between high
concentrations of plasma I-FABP and extensive intestinal damage among Zimbabwean infants.
Though Prendergast et al. (2014) found no significant association between I-FABP and stunted
growth, another study (Guerrant et al. 2016) conversely discovered a strong positive association
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between I-FABP and stunted growth among Brazilian children. In addition, Uddin and
colleagues (2016) found a positive association between I-FABP and anti-LPS
(lipopolysaccharide) antibodies during intestinal infection in children with EED. Altogether,
these findings suggest that enterocyte damage can be quantified by measuring I-FABP levels
with commercially available human ELISA assay kits and act as a biomarker of EED (Funaoka
et al., 2011; Uzun et al., 2014; Prendergast et al., 2015; Guerrant et al., 2016).
The following investigation therefore had two primary aims for each EED biomarker
candidates. Aim 1: to optimize a protocol for the use of DBS samples and a commercially
available human ELISA kit to examine transferrin and I-FABP concentrations. Aim 2: to
measure levels of transferrin and I-FABP in matched plasma/DBS samples to evaluate the
effectiveness and reliability of the DBS-optimized protocol in measuring biomarker levels
compared to traditional plasma measurements. This study builds on ongoing efforts to validate
minimally invasive, field-appropriate protocols for biomarker evaluation and incorporate
biochemical perspectives into anthropological research.
METHODS
Aim 1: Protocol Optimization
Transferrin
Dried blood spot samples collected from thirteen healthy adults were used for the initial
protocol validation of the commercially available human transferrin ELISA kit selected for this
study (Invitrogen Human Transferrin ELISA Kit, ThermoFisher Scientific, Carlsbad, California).
Based on estimates of normal concentrations of circulating transferrin, the amount present in a
single 3.2 mm DBS disk, and the high rate of sample dilution required by the kit, it was
determined that we would begin with the smallest possible sample amount. One 3.2 mm DBS
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sample disc was eluted overnight in 80 µL of Assay Diluent D provided in the kit. Five µL of
reconstituted sample was then diluted in 1.25 mL of Assay Diluent D, which yielded transferrin
concentrations within the assay’s detection range (1.029-750 ng/mL).
I-FABP
Dried blood spot samples collected from three healthy adults were used for the initial
protocol validation of the commercially available human I-FABP ELISA kit selected for this
study (Quantikine Human I-FABP Immunoassay, R&D Systems, Minneapolis, Minnesota).
Because of the relatively lower concentrations in I-FABP in blood plasma, the kit recommended
a limited dilution protocol for plasma samples. To ensure sufficient I-FABP presence in DBS
samples, we experimented with using multiple DBS punches in different levels of assay diluent.
The research team experimented with using 1, 2, 4, 6, and 8 DBS sample discs for each adult.
Additionally, for samples with more than 1 DBS hole punch, the research team assessed whether
150 or 175 µL of Calibrator Diluent provided in the kit was necessary to elute the samples
overnight (Table 1).
Though all dilution protocols yielded readings within the assay’s detection range (0-1000
pg/mL), further experimentation using 1 DBS hole punch in 125 µL of Calibrator Diluent
suggested high variability in sample reconstitution, with intra-assay CVs ranging from 0-59.3%.
However, I-FABP readings did not linearly or predictably increase when over 2 DBS sample
discs were used, which indicated a problematic variability in sample reconstitution when using
too many DBS sample discs. Lastly, increasing the volume of Calibrator Diluent from 150 to 175
µL yielded no significant benefits. Thus, the final dilution protocol selected for Aim 2 of this
study consisted of two 3.2 mm DBS hole punches eluted overnight in 150 µL of Calibrator
Diluent.
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Table 1
Protocol Optimization Dilution Combinations

Aim 2: Matched Plasma/DBS Analysis
Approval for the study was obtained from the Institutional Review Board of the
University of Pennsylvania. Healthy adults aged 18-45 from the University of Pennsylvania
community were recruited via word-of-mouth, electronic mailing lists, and flyers posted
throughout campus. Recruitment and data collection took place between September and October
of 2021. All participants were first screened to confirm their eligibility, and all participants
provided informed consent before data collection. People with known, mental or physical
chronic conditions, liver diseases, kidney diseases, blood clotting disorders, and currently
pregnant or breastfeeding were excluded from the study.
All participants arrived at the study site fasted for a minimum of three hours prior to data
collection. Upon arrival, all participants reviewed and signed the informed consent document
while research team members answered any remaining questions prior to proceeding with the
study. To maintain confidentiality, all participants were assigned a study participant ID number
which was used on all study materials (i.e., qualitative surveys, records of anthropometric data,
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and biological samples). The research team provided snacks and water and monitored all
participants for adverse reactions for a minimum of 15 minutes following data collection. All
participants were fairly compensated for their time with an Amazon or Acme gift card of their
choice.
Surveys and Anthropometric Data
The research team distributed qualitative surveys assessing participants’ demographic
and health backgrounds. For health backgrounds, the survey assessed factors known to impact
biomarker levels and intestinal function (e.g. experiences of gastrointestinal distress or exposures
to unsafe drinking water in the past 6 months). A research team member was present at all times
during survey completion to answer any questions and/or clarify survey content. Following
survey completion, trained research assistants used a portable stadiometer (Seca 213 Stadiometer,
Seca, Hanover, Maryland) to measure participants’ height and a scale (OMRON HBF-516B
Body Composition Monitor and Scale, OMRON Healthcare, Inc., Lake Forest, Illinois) to
measure participants’ weight.
Dried Blood Spots
Trained research assistants collected five ~50 µL drops of blood from a fingerstick onto
standardized filter paper cards (Whatman #903, GE Healthcare, Pascataway, New Jersey),
labelled “fDBS” samples by the researchers. All fDBS cards were left out at room temperature to
dry overnight, then stored at -25oC until analysis.
Phlebotomy
A trained phlebotomist drew 4 mL of venous whole blood into BD Vacutainer tubes from
participants’ arms. Five 50 µL drops of venous blood were subsequently pipetted onto filter
paper to make additional DBS cards (labelled “wbDBS”). All wbDBS cards were left out at
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room temperature to dry overnight, then stored at -25oC until analysis. The remaining whole
blood was centrifuged at 1500g for 15 minutes to separate plasma as supernatant. Plasma
samples were then aliquoted and stored at -80oC until analysis.
Transferrin ELISA Assay Protocol
The following protocol is a modified version of a commercially available human
transferrin ELISA kit designed for use with serum or plasma samples (Invitrogen Human
Transferrin ELISA Kit, ThermoFisher Scientific, Carlsbad, California). All reagents provided in
the kit were prepared and diluted according to the kit manual’s specifications.
On the afternoon prior to the assay run, one 3.2 mm disc was removed from each DBS
sample with a hole punch, transferred to a glass tube, and eluted overnight in 80 µL of Assay
Diluent D provided in the kit at 5oC. On the day of the run, samples were gently homogenized at
room temperature for one hour at 300 RPM, after which 5 µL of the eluted samples were further
diluted in 1.25 mL of Assay Diluent D. Two µL of thawed plasma was diluted in 998 µL of
Assay Diluent D; 10 µL of diluted plasma was then further diluted in 390 µL of Assay Diluent D.
All subsequent steps of the ELISA assay followed the protocol specified in the manufacturer’s
kit manual (see Appendix A).
I-FABP ELISA Assay Protocol
The following protocol is a modified version of a commercially available human I-FABP
ELISA kit designed for use with serum or plasma samples (Quantikine Human I-FABP
Immunoassay, R&D Systems, Minneapolis, Minnesota). All reagents provided in the kit were
prepared and diluted according to the manufacturer’s specifications.
On the afternoon prior to the run, two 3.2 mm diameter discs were extracted from the
filter paper cards using a hydraulic hole punch into a glass tube, and then eluted overnight in 150
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µL of Calibrator Diluent provided in the kit at 5oC. The morning of the assay run, samples were
gently homogenized at room temperature for one hour at 300 RPM, while 50 µL of thawed
plasma samples were diluted in 200 µL of Calibrator Diluent. All subsequent steps of the ELISA
assay followed the protocol specified in the manufacturer’s kit manual (see Appendix B).
Statistical Analyses
For all assays, three controls representing high, medium, and low biomarker
concentrations were selected from available samples and included to calculate inter-assay
coefficients of variation (CVs). For transferrin, all assay runs which yielded poor standard curves
and individual samples which yielded an intra-assay CV greater than 10%, as specified in the
manufacturer’s kit manual, were re-analyzed in subsequent assay runs. For I-FABP, all assay
runs which yielded poor standard curves and individual samples which yielded an intra-assay CV
greater than 12% were re-analyzed in subsequent assay runs. Participant survey and
anthropometric data variables were analyzed with standard descriptive summaries (i.e. means
and standard deviations for continuous variables and percentages for categorical variables).
Passing-Bablok regressions were used to assess the correlation between plasma and DBS
measurements of biomarker levels. Bland-Altman analyses were used to assess the agreement
between the plasma and DBS measurement methods. All statistical analyses were completed in
Microsoft Excel and R Version 4.1.2 and are consistent with those used in previous biomarker
validation studies (Eick et al., 2016; Hoke et al., 2018).
RESULTS
Out of 216 total respondents, 101 eligible participants were recruited for the study.
Twenty-seven participants were withdrawn after exhibiting immediate, adverse reactions to the
fingerstick or venous blood draw (e.g., dizziness, nausea, faintness), or due to an inability to
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locate a vein after two attempts. For transferrin, 12 incomplete samples were excluded from all
analyses due to limited biospecimen availability for assay re-runs. One additional sample was
identified as an outlier and excluded from analyses. For I-FABP, 11 samples were excluded from
all analyses due to dilution errors in one of the initial assay runs, while 2 were excluded from the
analysis of the relationship between fDBS and plasma samples due to different collection dates
of the biospecimens.
Transferrin
Sixty-one healthy adults between the ages of 18 and 45 were included for the analysis of
the transferrin validation study. Final population demographics and anthropometric
measurements for the sample are reported below (Table 2). The mean age of the sample was
22.15 years (SD = 4.60 years) and 68.85% of participants reported being biologically designated
as “female” at birth. Most participants identified as White (55.74%) or Asian (39.34%), followed
by Black (6.56%), Latinx (3.28%), Indigenous (1.64%), or Middle East / North African (1.64%).
The average height of the participants was 1.69 m (SD =.08 m); the average weight was 65.21 kg
(SD = 13.22 kg); and the average BMI was 22.85 kg/m2 (SD = 3.69 kg/m2).
Table 2
Descriptive Statistics of Participants Included for Transferrin Analysis
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All inter-assay coefficients of variation (CVs) exceeded 12%, the acceptable threshold
outlined by the assay kit manufacturer’s specifications (Table 3). For the low, medium, and high
controls, the inter-assay CVs were 23.20%, 18.50%, and 30.50%, respectively. Mean intra-assay
CVs fell within the kit manufacturer’s specifications of <10%; for fDBS, wbDBS, and plasma
samples, the mean CVs were 9.10%, 8.92%, and 9.88%, respectively.
Table 3
Transferrin Assay Coefficients of Variability (CVs)
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Matched DBS and Plasma Analysis
For fDBS vs. plasma samples, a Passing-Bablok regression yielded a model with slope
0.72. However, a Pearson’s r (59) = 0.432, p < .0005 indicated that while a significant
association existed, the average fDBS samples were not linearly and proportionally lower than
average plasma samples (Figure 1).
Figure 1
Regression Model for Plasma vs. fDBS Transferrin Levels

Note. The full equation generated from the Passing-Bablok regression fit is as follows: y = 0.72x
– 1.60.
For wbDBS vs. plasma samples, a Passing-Bablok regression yielded a model with slope
0.60. However, a Pearson’s r (59) = 0.463, p < .0001 indicated that while a significant
association existed, the average wbDBS samples were not linearly or proportionally lower than
average plasma samples (Figure 2).
Figure 2
Regression Model for Plasma vs. wbDBS Transferrin Levels
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Note. The full equation generated from the Passing-Bablok regression fit is as follows: y = 0.60x
+ 1.74.
Given the poor strength of the linear relationship between DBS and plasma samples and
the inconsistency across runs based on the interassay CVs for control samples, Bland-Altman
analyses were not conducted.
I-FABP
Sixty-one healthy adults between the ages of 18 and 45 were included for final analysis
of the relationship between fDBS and plasma samples, while sixty-three were included for final
analysis of the relationship between wbDBS and plasma samples. Final population demographics
and anthropometric measurements for the sample are reported below (Table 4). The mean age of
the sample was 22.05 years (SD = 4.62 years) and 66.67% of participants were biologically
designated as “female” at birth. Most participants identified as White (55.56%) or Asian
(41.27%), followed by Black (6.35%), Latinx (3.18%), Indigenous (1.59%), or Middle East /
North African (1.59%). The average height of the participants was 1.68 m (SD =.07 m); the
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average weight was 65.01 kg (SD = 13.92 kg); and the average BMI was 22.92 kg/m2 (SD = 3.83
kg/m2).
Table 4
Descriptive Statistics of Participants Included for I-FABP Analysis

All calculated coefficients of variation (CVs) fell within an acceptable range outlined by
the assay kit manufacturer’s specifications (Table 5). For the low, medium, and high controls, the
inter-assay CVs were 11.70%, 7.80%, and 9.10%, respectively. For fDBS, wbDBS, and plasma
samples, the mean intra-assay CVs were 3.35%, 3.02%, and 1.88%, respectively.
Table 5
I-FABP Assay Coefficients of Variability (CVs)
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fDBS and Plasma Analysis
A Passing-Bablok regression yielded a model with slope 13.09, and a Pearson’s r (59) =
0.873, p < .0001 indicated that average fDBS samples were linearly and proportionally lower
than average plasma samples (Figure 3).
Figure 3
Regression Model for Plasma vs. fDBS I-FABP Levels

Note. The full equation generated from the Passing-Bablok regression fit is as follows: y =
13.09x – 216.07.
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For the Bland-Altman analysis, fDBS values were then converted to their plasma
equivalents using the linear relationship yielded from the Passing-Bablok regression. Assessment
of the percentage difference between the two measurement methods revealed no significant
proportional bias (% bias: -0.134%; 95% CI: -67.698% to 67.430%) (Figure 4).
Figure 4
Bland-Altman Plot for fDBS vs. Plasma

wbDBS and Plasma Analysis
A Passing-Bablok regression yielded a model with slope 12.56, and a Pearson’s r (61) =
0.938, p < .0001 indicated that average wbDBS samples were linearly and proportionally lower
than average plasma samples (Figure 5).
Figure 5
Regression Model for Plasma vs. wbDBS I-FABP Levels
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Note. The full equation generated from the Passing-Bablok regression fit is as follows: y =
12.56x – 245.17.
For the Bland-Altman analysis, wbDBS values were again converted to their plasma
equivalents using the linear relationship yielded from the Passing-Bablok regression. Assessment
of the percentage difference between the two measurement methods revealed no significant
proportional bias (% bias: -0.471%; 95% CI: -46.583% to 47.526%) (Figure 6).
Figure 6
Bland-Altman Plot for wbDBS vs. Plasma
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DISCUSSION
Transferrin
Statistical analyses of the DBS-based protocol revealed that transferrin is not compatible
with the DBS sampling method. Though average wbDBS transferrin levels exhibited a slightly
stronger correlation with plasma, the low Pearson’s r values for both fDBS and wbDBS indicated
that plasma and DBS concentrations of transferrin are not linearly and proportionally correlated.
Thus, DBS transferrin levels could not be easily converted to plasma estimates, and BlandAltman analyses could not be completed. The inter-assay CVs additionally suggested a poor
consistency between individual assay runs, even though the same protocol was followed for
every ELISA assay, and substantiated the poor viability of using DBS to measure transferrin.
Additionally, several limiting factors support the lack of validity of using DBS to
evaluate transferrin status. Physiologically, a large amount of iron is necessary for red blood cell
production and maintenance, meaning that erythrocyte uptake of transferrin is likely significant
(Anderson and Frazer, 2017). Unlike plasma, which contains no erythrocytes, red blood cells are
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often lysed during DBS whole blood collection, which may lead to an unpredictable release
some transferrin during sampling. Tissues with a higher proliferative capacity, such as the distal
capillaries punctured to collect fDBS samples, often also express greater transferrin receptors to
meet their increased iron need (Anderson and Frazer, 2017). Therefore, capillary blood cells may
uptake transferrin to a greater degree than venous blood cells, which may be one reason for the
stronger correlation between wbDBS and plasma transferrin relative to the relationship between
fDBS and plasma transferrin (additional reasons are discussed under I-FABP).
As for the protocol itself, all blood samples and reagents required significant dilution,
with dilution factors ranging from 5 to 20,000. Given that blood sample quantities ranged from
1-10 µL, an error of even 1 mL could notably alter results, and account for the high inter-assay
variability. Furthermore, we observed that high quantities of Assay Diluent D often caused the
blood samples to become extremely viscous, especially the plasma samples. The increased
viscosity made consistent pipetting extremely difficult, introduced a major source of intra-assay
variability, and required biological samples to be analyzed multiple times during the study. As a
result, these factors increased, rather than decreased, the burden of assessing transferrin levels in
a timely and scientifically rigorous manner.
The primary limitation of focusing on iron deficiency and using transferrin as a
biomarker for EED-related nutrient malabsorption is that low iron levels and anemia can be
caused by multiple reasons. Iron levels are highly sensitive to numerous daily lifestyle factors,
including menstruation in biological females, dietary intake, and physical activity. Iron
sequestration, anemia, and elevated circulating transferrin also have anti-inflammatory effects
against bacterial infections, another key feature of EED (Anderson and Frazer, 2017; Ardehali et
al., 2004). Thus, while the role of iron-deficiency anemia in infant growth and intestinal health
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warrants further investigation, disentangling all these influencing factors to identify EED-related
micronutrient malabsorption cannot be directly measured through transferrin status alone.
While the present DBS transferrin protocol is not an appropriate measure of EED-related
nutrient malabsorption, important future directions include the validation of minimally invasive
techniques to assess EED-related malabsorption of other nutrients. In the 1970s, jejunal biopsies
from a cohort of Peace Corps volunteers in Pakistan retrospectively suspected to have EED
revealed abnormal carbohydrate absorptive function, which was eventually reversed 2-3 years
after their return to the U.S. (Korpe and Petri, 2012). Several EED studies have since evaluated
carbohydrate absorption through the urinary ratio of lactulose, a sugar which normally cannot
cross the intestinal barrier, to mannitol, a sugar that can cross the intestinal barrier (Keusch et al.,
2014). However, this method requires collecting multiple urine samples over the course of
several hours, demonstrating a pressing need for more time-efficient, minimally invasive
techniques for assessing EED-related nutrient malabsorption.
I-FABP
This validation study reveals that DBS can be used to measure I-FABP levels with
acceptable reliability, precision, and sensitivity compared to plasma. Our analyses revealed a
high level of correspondence between matched plasma and DBS readings of I-FABP in our
sample, with wbDBS samples exhibiting a slightly stronger relationship with plasma than the
fDBS samples. Though plasma samples consistently generated higher concentrations of I-FABP
compared to their DBS counterparts, the regression model suggested there is a linear,
proportional relationship which will allow researchers to convert between DBS and plasma IFABP readings. Lastly, the Bland-Altman analyses indicated no significant, constant bias
between the plasma- and DBS-based I-FABP measurement methods.
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Differences between the fDBS and wbDBS samples must be considered when evaluating
their linear relationships with plasma I-FABP readings. First, the wbDBS samples were created
in ideal laboratory conditions: a pipette ensured that exactly five 50 µL drops of venous blood
were collected and dried on DBS filter paper cards. Comparatively, the number and volume of
blood drops collected via fingerstick often varied due to factors that impacted participants’ distal
blood circulation, such as level of physical activity or hydration prior to collection, and overall
body temperature. Furthermore, collecting blood via fingerstick as opposed to pipetted blood is
at greater risk for interference from detritus in the immediate environment, such as skin cells
from the puncture. Second, the fDBS samples were collected from more distal finger capillaries,
whereas the wbDBS and plasma samples were collected from the same, more proximal arm
veins. I-FABP is specifically expressed in the epithelial cells of the small intestinal mucosal
barrier and is released first into the intestinal circulation following enterocyte damage (Funaoka
et al., 2011). Thus, circulating I-FABP levels are expected to vary in different parts of the body.
Therefore, the stronger linear relationship between wbDBS and plasma I-FABP compared to the
relationship between fDBS and plasma I-FABP was expected.
The validation of I-FABP introduces a new, salient DBS biomarker of EED and is an
important step towards understanding the pathophysiology of this complex disorder. The small
intestinal barrier is critical for maintaining homeostasis and promoting normal physiological
development, and early detection of EED is crucial to prevent compounding adverse health
effects among young children (Walrath et al., 2021; Harper et al., 2018). To our knowledge, this
is the first study to validate I-FABP’s measurement using minimally invasive sampling, and our
findings build on a rapidly growing literature on DBS biomarker validation (Brindle et al., 2010;
Crimmins et al., 2014; Eick et al., 2016; Eshghi et al., 2020; Lacher et al., 2013; Hoke et al.,
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2018; Samuelsson et al., 2015). I-FABP’s value as a biomarker of intestinal permeability and
dysfunction has been widely acknowledged and investigated within the context of numerous
diseases besides EED, ranging from enterocolitis to secondary organ failure (Coufal et al., 2020;
Ng et al., 2013; Voth et al., 2015; Wiercinska-Drapalo et al., 2008). However, these studies
relied on conventional biological sampling and were limited to clinical settings with extensive
laboratory infrastructure. Logistically, this minimally invasive, field-friendly DBS protocol
greatly expands the potential settings and populations in which intestinal permeability, and
therefore intestinal dysfunction, can be assessed at the biochemical level.
Some limitations must be considered when evaluating this study. First, our study consists
of a relatively small sample size compared to other DBS biomarker validation studies (Crimmins
et al., 2014; Samuelsson et al., 2015). Second, the study has not yet completed a ‘spike-andretrieval’ experiment, in which whole blood is spiked with known quantities of an analyte
(McDade, 2014). Therefore, the absolute accuracy of the selected human I-FABP ELISA kit is
unknown at the time of this writing. Third, the long-term stability of I-FABP in DBS samples is
unknown; though analyte degradation to some degree is expected, the extent to which this
impacts the accuracy of I-FABP measurement is unclear. Lastly, this study occurred in a setting
with comprehensive, easily accessible laboratory infrastructure, but the development of this
method is intended for use in low-resource and non-clinical field settings as well. I-FABP’s
stability in DBS samples in under different storage conditions is currently unknown and thus
warrants further investigation. Despite these limitations, there is reasonable evidence supporting
the validity of this I-FABP DBS protocol.
Immediate future directions therefore include the completion of a spike-and-retrieval
experiment and the evaluation of I-FABP’s stability in DBS samples over time and under
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different storage conditions. The former involves spiking whole blood with different, predetermined concentrations of Human FABP2 Standard solution provided in the kit. The spiked
whole blood is used to create DBS samples, which are then analyzed for accuracy following the
developed protocol (McDade, 2014). Long-term stability involves analyzing DBS samples at
multiple time intervals and assessing the degree to the analyte degrades over time and across
multiple freeze (McAllister et al., 2015). Exposing DBS cards to variable temperatures (e.g., 4oC,
room temperature, and 37oC) or oscillating temperature patterns (e.g., 12 hours at 32oC and 12
hours at 22oC) is also necessary to evaluate analyte stability in possible, extreme field conditions
in which this technique will be used (McAllister et al., 2015; McDade, 2014). Finally,
researchers recommend comparing DBS samples which have never been thawed to DBS samples
that have undergone multiple cycles of freezing and thawing; the same DBS samples are often
used for multiple analyses, and analytes may degrade over multiple removals from the freezer
during assay preparations (McDade, 2014; Eick et al., 2016; McDade et al., 2014).
Other future directions include measuring I-FABP in tandem with other biomarkers of
EED, like EndoCAb, and validating additional candidate biomarkers for DBS sampling,
including lipopolysaccharide-binding protein (LBP). LBP binds to bacterial cell walls and
initiates a signaling cascade to mount an immune response to pathogens, and acts as a biomarker
of systemic inflammation (Harper et al., 2018). Previous studies have indicated that elevated
LBP levels are associated with villous blunting, intestinal permeability, and elevated I-FABP
levels, making it a particularly promising EED biomarker (Amadi et al., 2017; Guerrant et al.,
2016; Marie et al., 2018). Ongoing efforts to understand how EED impacts individual- and
population-level health have thus far been impeded by unclear diagnostic criteria, and the
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combined use of other EED biomarkers with I-FABP may elucidate biochemical mechanisms to
clearly define the boundaries of this disorder (Harper et al., 2018).
Lastly, further validation of this DBS I-FABP protocol must be conducted in other
populations, particularly among young children and infants who are most severely affected by
EED. Our study population largely consisted of relatively young adults, with a mean age of
approximately 22 years old. However, previous studies have observed variability in I-FABP
levels in both infants and older adults, age ranges which were not included in this initial
validation study (Shores et al., 2020; Walrath et al., 2021). Moreover, our study population had
relatively healthy gut functioning, with only a handful of participants yielding higher than
expected I-FABP levels. Given the imperfection of the linear correlations at the higher range of
I-FABP levels (Figures 1 and 3) and the limited number of participants with increased intestinal
permeability in this study, future studies in populations that experience greater intestinal distress
are warranted.
CONCLUSION
This study adapted and validated the use of DBS sampling with a commercially available
ELISA kit for the measurement of I-FABP but found DBS sampling of transferrin to be an
invalid measurement method. There was a statistically significant linear correlation between
DBS and plasma I-FABP levels and a high level of agreement between the two measurement
methods; however, there was a statistically insignificant linear correlation between DBS and
plasma transferrin levels. This method contributes to a growing body of DBS biomarker research
and facilitates the study of EED and intestinal permeability in low-resource, non-clinical settings.
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Appendix A
Full Transferrin ELISA Protocol
Following sample preparation, 100 µL of all samples were loaded in duplicate to
microtiter plate wells coated with transferrin antibodies. Samples were incubated for 2.5 hours
with gentle shaking at room temperature, then washed using a plate washer as directed by the kit
manual. Prepared biotin conjugate was added to the wells, which was then similarly incubated
for an additional hour at room temperature and washed. Streptavidin-HRP solution was added to
the wells and incubated for 45 minutes at room temperature. After the final wash, a solution of
TMB substrate was added to each well and the enzyme reaction was allowed to proceed at room
temperature for 30 minutes. Stop solution was then added, and optical densities were read at 450
nm within 30 minutes of adding the stop solution.
Appendix B
Full I-FABP ELISA Protocol
On the day of the assay run, 50 µL of Assay Diluent RD1-63 were first loaded into all
microtiter plate wells coated with I-FABP antibodies, followed by 50 µL of all standards and
samples in duplicate. Samples were incubated for 2 hours at room temperature on a horizontal
orbital microplate shaker at 500 rpm, then washed with I-FABP Wash Buffer in a plate washer,
as directed by the kit manual. Next, 200 µL of prepared Human I-FABP2 Conjugate was added
to each well, and then similarly incubated for 2 hours and washed. Following this, 6 mL of Color
Reagents A and B were used to prepare 12 mL of Substrate Solution; 200 µL of Substrate
Solution was then added to each well, after which the plate was covered, incubated for 30
minutes, and washed. Last, 50 µL of prepared Stop Solution was added to each well, and the
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plate was incubated for 15 minutes at room temperature at 200 rpm. Optical densities were read
at 450 nm within 30 minutes of adding Stop Solution.

